AIM ImmunoTech Q2 2024 GAAP EPS $(0.03) Beats $(0.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
AIM ImmunoTech (AMEX:AIM) reported Q2 2024 GAAP EPS of $(0.03), beating the analyst estimate of $(0.12) by 75%. The company also reported quarterly sales of $50,000, surpassing the estimate of $11,670 by 328.57%, and marking a 19.05% increase from the same period last year.
August 16, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.03) beating the $(0.12) estimate and sales of $50,000 surpassing the $11,670 estimate. This indicates strong performance and could positively impact the stock price in the short term.
The significant beat on both EPS and sales estimates suggests strong operational performance, which is likely to boost investor confidence and positively impact AIM's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100